CUE (Cue Biopharma) Cyclically Adjusted Book per Share: $49.40 (As of Mar. 2026)


CUE Cue Biopharma Inc CUE
59 GF Score
Price $28.33
GF Value $62.36
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma Cyclically Adjusted Book per Share?

Cue Biopharma CUE -0.28% 59 Cyclically Adjusted Book per Share is $49.40 as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.36 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cue Biopharma's adjusted book value per share for the three months ended in Mar. 2026 was $6.638. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $49.40 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-03), Cue Biopharma's current stock price is $28.33. Cue Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $49.40. Cue Biopharma's Cyclically Adjusted PB Ratio of today is 0.57.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Cue Biopharma was 0.71. The lowest was 0.11. And the median was 0.49.


Cue Biopharma  (NAS:CUE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cue Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=28.33/49.40
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Cue Biopharma was 0.71. The lowest was 0.11. And the median was 0.49.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cue Biopharma Cyclically Adjusted Book per Share Related Terms


Cue Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Cyclically Adjusted Book per Share Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 49.40

CUE vs ALPS, AARD, KLRS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Cue Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Cyclically Adjusted PB Ratio falls into.


CUE
59GF Score
Cue Biopharma Inc CUE
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cue Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.638/330.2130*330.2130
=6.638

Current CPI (Mar. 2026) = 330.2130.

Cue Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201512 10.084 236.525 14.078
201609 0.000 241.428 0.000
201612 22.057 241.432 30.168
201703 0.000 243.801 0.000
201706 12.590 244.955 16.972
201709 6.368 246.819 8.520
201712 89.545 246.524 119.943
201803 82.328 249.554 108.937
201806 73.371 251.989 96.147
201809 58.724 252.439 76.816
201812 49.233 251.233 64.710
201903 35.697 254.202 46.371
201906 28.565 256.143 36.825
201909 35.277 256.759 45.369
201912 61.677 256.974 79.255
202003 51.056 258.115 65.317
202006 82.041 257.797 105.087
202009 86.858 260.280 110.195
202012 77.975 260.474 98.852
202103 68.504 264.877 85.402
202106 69.504 271.696 84.474
202109 60.266 274.310 72.548
202112 61.036 278.802 72.291
202203 56.781 287.504 65.216
202206 50.684 296.311 56.483
202209 43.020 296.808 47.862
202212 45.771 296.797 50.924
202303 38.233 301.836 41.827
202306 31.553 305.109 34.149
202309 28.368 307.789 30.435
202312 23.561 306.746 25.363
202403 18.531 312.332 19.592
202406 13.339 314.175 14.020
202409 12.639 315.301 13.237
202412 8.491 315.605 8.884
202503 3.193 319.799 3.297
202506 7.127 322.561 7.296
202509 5.108 324.800 5.193
202512 8.206 324.054 8.362
202603 6.638 330.213 6.638

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $49.40 mean?
Cue Biopharma (CUE) has a Cyclically Adjusted Book per Share of $49.40 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cue Biopharma and its competitors.
Is Cue Biopharma's Cyclically Adjusted Book per Share too high?
Cue Biopharma's current Cyclically Adjusted Book per Share is $49.40. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Cyclically Adjusted Book per Share compare to ALPS and AARD?
Cue Biopharma's Cyclically Adjusted Book per Share of $49.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Cyclically Adjusted Book per Share is $49.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.36, compared to a current price of $28.33 — trading 54.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is $49.40. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Cyclically Adjusted Book per Share is $49.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $28.33 is trading 54.6% below its estimated GF Value™ of $62.36. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Cyclically Adjusted Book per Share: $49.40
  • GF Value™: $62.36 vs. price of $28.33 (54.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score

Get the complete analysis for CUE

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.33
Price
$62.36
GF Value